MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
https://doi.org/10.17650/1818-8346-2016-11-4-25-31
Abstract
ALK-positive anaplastic large cell lymphoma is a heterogeneous group of mature T-cell non-Hodgkin lymphoma, and is characterized by CD30/Ki-1 expression. Recently, value of various prognostic factors is investigated. These include clinical, histological and molecular genetic changes associated with different signaling pathways activation. Some features of the mechanism of action of anaplastic lymphoma kinases and targeted therapies possibilities addressed in this review.
About the Authors
E. V. Chernyshova
Federal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy Rogachev
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
D. S. Abramov
Federal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy Rogachev
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
D. M. Konovalov
Federal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy Rogachev
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
S. S. Larin
Federal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy Rogachev
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
N. V. Myakova
Federal Research Сentre of Pediatric Hematology, Oncology, and Immunology named after Dmitriy Rogachev
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
Russian Federation
1 Samory Mashela St., Moscow 117997, Russia
References
1. Stein H., Mason D.Y., Gerdes J. et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66(4):848–58. PMID: 3876124.
2. Kinney M.C., Higgins R.A., Medina E.A. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch Pathol Lab Med 2011;135(1):19–43. DOI: 10.1043/2010–0507-RAR. 1. PMID: 21204709.
3. Wright D., McKeever P., Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children’s Cancer Study Group. J Clin Pathol 1997;50(2):128–34. PMID: 9155693.
4. Boi M., Zucca E., Inghirami G., Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. Br J Haematol 2015;168(6):771–83. DOI: 10.1111/bjh.13265. PMID: 25559471.
5. Benharroch D., Meguerian-Bedoyan Z., Lamant L. et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998;91(6):2076–84. PMID: 9490693.
6. Falini B., Bigerna B., Fizzotti M. et al. ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol 1998;153(3):875–86. DOI: 10.1016/S0002-9440(10)65629-5. PMID: 9736036.
7. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, 2008.
8. Krenacs L., Wellmann A., Sorbara L. et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of Tand null-cell type and Hodgkin’s disease: evidence for distinct cellular origin. Blood 1997;89(3):980–9. PMID: 9028330.
9. Bonzheim I., Geissinger E., Roth S. et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004;104(10):3358–60. DOI: 10.1182/blood-2004-03-1037. PMID: 15297316.
10. Lamant L., McCarthy K., d’Amore E. et al. Prognostic impact of morphologic and phenotypic features of childhood ALK- positive anaplastic large-cell lymphoma: Results of the ALCL99 Study. J Clin Oncol 2011;29(35):4669–76. DOI: 10.1200/JCO. 2011.36.5411. PMID: 22084369.
11. Brugières L., Deley M.C., Pacquement H. et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998;92(10):3591–8. PMID: 9808552.
12. Seidemann K., Tiemann M., Schrappe M. et al. Short-pulse B-non-Hodgkin lymphoma- type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 2001;97(12):3699–706. PMID: 11389005.
13. Williams D.M., Hobson R., Imeson J. et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol 2002;117(4):812–20. PMID: 12060115.
14. Le Deley M.C., Reiter A., Williams D. et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 2008;111(3):1560–6. DOI: 10.1182/blood-2007-07-100958. PMID: 17957029.
15. Morris S.W., Kirstein M.N., Valentine M.B. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994;263(5151):1281–4. PMID: 8122112.
16. Hernández L., Pinyol M., Hernández S. et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFGALK translocations. Blood 1999;94(9): 3265–8. PMID: 10556217.
17. Touriol C., Greenland C., Lamant L. et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95(10):3204–7. PMID: 10807789.
18. Tort F., Pinyol M., Pulford K. et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001;81(3):419–26. PMID: 11310834.
19. Ma Z., Hill D.A., Collins M.H. et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003;37(1):98–105. DOI: 10.1002/gcc.10177. PMID: 12661011.
20. Soda M., Choi Y.L., Enomoto M. et al. Identification of the transforming EML4- ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561–6. DOI: 10.1038/nature05945. PMID: 17625570.
21. Cools J., Wlodarska I., Somers R. et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002;34(4):354–62. DOI: 10.1002/gcc.10033. PMID: 12112524.
22. Lamant L., Dastugue N., Pulford K. et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93(9): 3088–95. PMID: 10216106.
23. Takeuchi K., Choi Y.L., Togashi Y. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15(9):3143–9. DOI: 10.1158/1078-0432.CCR-08-3248. PMID: 19383809.
24. Debelenko L.V., Arthur D.C., Pack S.D. et al. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003;83(9):1255–65. PMID: 13679433.
25. Panagopoulos I., Nilsson T., Domanski H.A. et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006;118(5):1181–6. DOI: 10.1002/ijc.21490. PMID: 16161041.
26. Delsol G., Lamant L., Mariamé B. et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997;89(5):1483–90. PMID: 9057627.
27. Griffin C.A., Hawkins A.L., Dvorak C. et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999;59(12):2776–80. PMID: 10383129.
28. Lawrence B., Perez-Atayde A., Hibbard M.K. et al. TPM3-ALK and TPM4ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157(2):377–84. DOI: 10.1016/S0002-9440(10)64550-6. PMID: 10934142.
29. Lamant L., Pulford K., Bischof D. et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156(5):1711–21. DOI: 10.1016/S0002-9440(10)65042-0. PMID: 10793082.
30. Powers C., Aigner A., Stoica G.E. et al. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002;277(16):14153–8. DOI: 10.1074/jbc.M112354200. PMID: 11809760.
31. Pillay K., Govender D., Chetty R. ALK protein expression in rhabdomyosarcomas. Histopathology 2002;41(5):461–7. PMID: 12405914.
32. Perez-Pinera P., Garcia-Suarez O., Menendez-Rodriguez P. et al. The receptor protein tyrosine phosphatase (RPTP) beta/zeta is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun 2007;362(1):5–10. DOI: 10.1016/j.bbrc.2007.06.050. PMID: 17706593.
33. Jazii F.R., Najafi Z., Malekzadeh R. et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006;12(44):7104–12. PMID: 17131471.
34. Hallberg B., Palmer R.H. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013;13(10):685–700. DOI: 10.1038/nrc3580. PMID: 24060861.
35. Ou S.H., Bazhenova L., Camidge D.R. et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010;5(12):2044–6. DOI: 10.1097/JTO.0b013e318200f9ff. PMID: 21102269.
36. Weickhardt A.J., Rothman M.S., Salian-Mehta S. et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012;118(21):5302–9. DOI: 10.1002/cncr.27450. PMID: 22488744.
37. Kwak E.L., Bang Y.J., Camidge D.R. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693–703. DOI: 10.1056/NEJMoa1006448. PMID: 20979469.
38. Chiarle R., Voena C., Ambrogio C. et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8(1):11–23. DOI: 10.1038/nrc2291. PMID: 18097461.
39. Pearson J.D., Lee J.K., Bacani J.T. et al. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma. Int J Clin Exp Pathol 2011;4(2):124–33. PMID: 21326808.
40. George S.K., Vishwamitra D., Manshouri R. et al. The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget 2014;5(14):5750–63. DOI: 10.18632/oncotarget.2170. PMID: 25026277.
41. Cui J.J., Tran-Dubé M., Shen H. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54(18):6342–63. DOI: 10.1021/jm2007613. PMID: 21812414.
42. Guo L., Zhang H., Shao W., Chen B. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Drug Des Devel Ther 2015;9:5491–7. DOI: 10.2147/DDDT.S91988. PMID: 26491259.
43. Cuyàs E., Pérez-Sánchez A., Micol V. et al. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle 2016:1–6. DOI: 10.1080/15384101.2016.1245249. PMID: 27753543.
44. Wang Y., Wang L., Guan S. et al. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep 2016;6:19423. DOI: 10.1038/srep19423. PMID: 26786851.
45. Moore N.F., Azarova A.M., Bhatnagar N. et al. Molecular rationale for the use of PI3K/ AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget 2014;5(18):8737–49. DOI: 10.18632/oncotarget.2372. PMID: 25228590.
Review
For citations:
Chernyshova E.V., Abramov D.S., Konovalov D.M., Larin S.S., Myakova N.V. MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA. Oncohematology. 2016;11(4):25-31. https://doi.org/10.17650/1818-8346-2016-11-4-25-31
Views:
11016
Email this article 